Neela Paykel - Dec 22, 2021 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role
Gen Counsel & Corp Secretary
Signature
/s/ John P. Condon, Attorney-in-Fact
Stock symbol
HYPR
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
4
Date filed
12/23/2021, 08:42 PM
Next filing
Feb 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HYPR Stock Option (right to buy) Award +98.3K 98.3K Dec 22, 2021 Class A Common Stock 98.3K $3.27 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vested as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following three years, subject to Ms. Paykel's continued service through the applicable vesting date.
F2 In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,
F3 a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), the option was received in the Mergers in exchange for a stock option to acquire 300,000 shares of Hyperfine common stock for $1.07.